Vericel records Q1 MACI revenue $46.3M (+15% YoY), raises FY profitability guidance

Vericel Corp

2025-Q1 EPS reported -$0.23 revenue$52,598,000

Record Q1 MACI revenue $46.3M (+15% YoY); total revenue $52.6M vs $51.3M YoY.
Net loss $11.2M ($0.23/diluted) vs $3.9M loss ($0.08) YoY; adjusted EBITDA $3.2M vs $7.2M.
Full-year revenue growth reaffirmed 20-23%; raised gross margin guidance to 74% and adjusted EBITDA margin to 26%.
~400 MACI Arthro surgeons trained; YTD biopsy growth >30% for trained surgeons; NexoBrid +207% YoY.
Cash $162M, no debt; tariffs expected negligible impact.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.